RX-3117: “Early responses were detected with an overall response rate of 38% in 24 subjects, and a disease control rate of 92% at 8 weeks.”; Metastatic pancreatic cancer

fluorocyclopentenylcytosine (RX-3117) - Rexahn

Jan 19, 2019